FIGURE 2.

The stability of urinary eicosanoids in participants (n=63), where corticosteroid (CS) treatment was unchanged, during scheduled study visits who had stable T2 biomarkers (Δ blood eosinophil count (BEC) ≤0.10×10⁹ cells·L⁻¹, Δ fractional exhaled nitric oxide (F_ENO) ≤10 ppb) and stable symptoms (Δ asthma control questionnaire (ACQ-7) ≤0.5) across scheduled visits (Baseline, Visit 3 and Visit 6), based on intra-class correlation (ICC) on serial measures. Samples taken from scheduled study visits. Restricted to visits where the participants were on the same CS treatment regimen. Pairwise comparison of visits where ΔACQ-7 ≤0.5, Δ blood eosinophil count ≤0.10×10⁹ cells·L⁻¹, Δ fractional exhaled nitric oxide ≤10 ppb.